Searle Past Earnings Performance
Past criteria checks 1/6
Searle's earnings have been declining at an average annual rate of -4.9%, while the Pharmaceuticals industry saw earnings growing at 4.1% annually. Revenues have been growing at an average rate of 16.1% per year. Searle's return on equity is 1.3%, and it has net margins of 0.9%.
Key information
-4.9%
Earnings growth rate
-8.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 20.2% |
| Revenue growth rate | 16.1% |
| Return on equity | 1.3% |
| Net Margin | 0.9% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Searle makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 33,898 | 314 | 8,443 | 0 |
| 31 Mar 23 | 34,139 | 1,157 | 8,690 | 0 |
| 31 Dec 22 | 32,198 | 1,564 | 8,213 | 0 |
| 30 Sep 22 | 30,445 | 1,730 | 7,760 | 0 |
| 30 Jun 22 | 29,910 | 2,352 | 7,372 | 0 |
| 31 Mar 22 | 28,422 | 3,555 | 7,178 | 0 |
| 31 Dec 21 | 28,408 | 3,604 | 7,088 | 0 |
| 30 Sep 21 | 28,335 | 3,929 | 6,983 | 0 |
| 30 Jun 21 | 26,220 | 3,679 | 6,659 | 0 |
| 31 Mar 21 | 25,366 | 2,931 | 6,025 | 0 |
| 31 Dec 20 | 22,965 | 2,877 | 5,589 | 0 |
| 30 Sep 20 | 21,075 | 2,589 | 5,461 | 0 |
| 30 Jun 20 | 20,475 | 2,500 | 5,531 | 0 |
| 31 Mar 20 | 19,791 | 2,192 | 5,629 | 0 |
| 31 Dec 19 | 19,179 | 2,055 | 5,653 | 0 |
| 30 Sep 19 | 18,644 | 2,111 | 5,504 | 0 |
| 30 Jun 19 | 18,062 | 2,241 | 5,305 | 0 |
| 31 Mar 19 | 17,675 | 2,126 | 5,226 | 0 |
| 31 Dec 18 | 17,134 | 2,278 | 5,067 | 0 |
| 30 Sep 18 | 16,537 | 2,570 | 4,958 | 0 |
| 30 Jun 18 | 16,148 | 2,687 | 4,744 | 0 |
| 31 Mar 18 | 15,246 | 2,934 | 4,528 | 0 |
| 31 Dec 17 | 14,496 | 2,716 | 4,486 | 0 |
| 30 Sep 17 | 13,933 | 2,389 | 4,171 | 0 |
| 30 Jun 17 | 13,310 | 2,356 | 4,025 | 0 |
| 31 Mar 17 | 12,962 | 2,049 | 4,054 | 0 |
| 31 Dec 16 | 12,327 | 2,250 | 3,531 | 0 |
| 30 Sep 16 | 11,978 | 2,248 | 3,231 | 0 |
| 30 Jun 16 | 11,328 | 2,032 | 3,031 | 0 |
| 31 Mar 16 | 10,558 | 1,981 | 2,620 | 0 |
| 31 Dec 15 | 10,219 | 1,784 | 2,455 | 0 |
| 30 Sep 15 | 9,603 | 1,582 | 2,331 | 0 |
| 30 Jun 15 | 9,048 | 1,373 | 2,204 | 0 |
| 31 Mar 15 | 8,868 | 1,212 | 2,161 | 0 |
| 31 Dec 14 | 8,371 | 1,042 | 2,062 | 0 |
| 30 Sep 14 | 8,143 | 875 | 2,069 | 0 |
| 30 Jun 14 | 7,609 | 802 | 1,961 | 0 |
| 31 Mar 14 | 7,080 | 979 | 1,842 | 0 |
| 31 Dec 13 | 6,793 | 850 | 1,728 | 0 |
| 30 Sep 13 | 6,383 | 831 | 1,512 | 0 |
| 30 Jun 13 | 6,014 | 669 | 1,423 | 0 |
Quality Earnings: SEARL has high quality earnings.
Growing Profit Margin: SEARL's current net profit margins (0.9%) are lower than last year (7.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SEARL's earnings have declined by 4.9% per year over the past 5 years.
Accelerating Growth: SEARL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SEARL had negative earnings growth (-86.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-3.3%).
Return on Equity
High ROE: SEARL's Return on Equity (1.3%) is considered low.